Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

57
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fabrication and evaluation of a bi-layered electrospun polyacrylonitrile/polycaprolactone-chitosan/gelatin/polyethylene oxide nanofibers containing antibiotics and nanoparticles: antibacterial and antibiofilm activity.

Scientific reports·2026
Same author

From Gene Expression to Candidate Biomarkers in Ulcerative Colitis: Aquaporin-9 in Neutrophil Extracellular Traps Formation Pathways.

Iranian journal of medical sciences·2026
Same author

Nanostructured Lipid Carriers Co-Loaded with Doxycycline, Gentamicin, and Thymol for Enhanced Intracellular Antibacterial Activity Against <i>Brucella melitensis</i>.

International journal of nanomedicine·2026
Same author

Bacteriophage therapy against American foulbrood in honey bees: a PRISMA-guided systematic review.

Frontiers in microbiology·2026
Same author

Antibacterial and antibiofilm activities of curcumin-mediated green-synthesised silver nanoparticles against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

BMC biotechnology·2026
Same author

Management of Diabetic Foot Infections Using Phage Therapy.

Infection and drug resistance·2026

Related Experiment Video

Updated: May 9, 2025

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

12.8K

Gut microbiomes and treatment-resistant ulcerative colitis: a case-control study using qPCR.

Amjad Ahmadi1,2, Leili Shokoohizadeh1,2, Farshad Sheikhesmaili3

  • 1Infectious Disease Research Center, Avicenna Institute of Clinical Sciences, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran.

BMC Microbiology
|April 28, 2025
PubMed
Summary

Investigating the gut microbiome in ulcerative colitis (UC) reveals significant differences between treatment-resistant and newly diagnosed patients. These microbiome variations may influence treatment outcomes and guide new therapeutic strategies for UC management.

Keywords:
Gut microbiomeUlcerative colitisqPCR

More Related Videos

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

27.6K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

226

Related Experiment Videos

Last Updated: May 9, 2025

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

12.8K
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

27.6K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

226

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • The gut microbiome plays a pivotal role in ulcerative colitis (UC) pathogenesis and progression.
  • Understanding the gut microbiome's function in refractory UC is crucial for developing effective treatment strategies.
  • This study investigates microbial differences in patients with varying UC severity and their relatives.

Purpose of the Study:

  • To explore the role of gut bacteria in patients with refractory ulcerative colitis (UC).
  • To compare the gut microbiome composition between newly diagnosed UC patients, treatment-resistant UC patients, and their healthy relatives.
  • To identify potential microbial biomarkers associated with UC treatment response.

Main Methods:

  • A case-control study involving four groups: new UC patients (n=24), treatment-resistant UC patients (n=23), relatives of new UC patients (n=24), and relatives of treatment-resistant UC patients (n=23).
  • Stool samples were analyzed using quantitative real-time PCR (qPCR) and culture.
  • Data on probiotic consumption and antibiotic use were collected via questionnaires.

Main Results:

  • No pathogenic bacteria were detected in any group.
  • A significant relationship was observed between specific microbial populations (E. coli, Bifidobacterium ssp.) in treatment-resistant UC patients and their relatives (Groups 2 and 4).
  • Significant differences in Lactobacillus ssp., Bifidobacterium ssp., and Bacteroides ssp. were found between newly diagnosed UC patients and treatment-resistant UC patients (Groups 1 and 2).

Conclusions:

  • Intestinal microbiome composition significantly impacts ulcerative colitis management.
  • Microbiome differences between treatment-resistant and newly diagnosed UC patients offer insights into treatment variability.
  • Findings suggest potential for microbiome-based therapies, including fecal microbiome transplantation (FMT), probiotics, and prebiotics, for UC.